
COLORADO TYPE 2 DIABETES REPORT 2007



Colorado Business Group on Health



Presented by

sanofi aventis

in conjunction with the Colorado Business Group on Health



CONTENTS

Introduction2
Colorado Springs 3-4
Denver 4–5
Fort Collins 6–7
Grand Junction 7-8
Greeley
Pueblo
Methodology12

www.coloradohealthonline.org

CBGH Members: The BEST Trust The Broadmoor Hotel City of Boulder City of Colorado Springs City of Littleton CoBank Colorado College Griffis Group Colorado Springs Utilities Colorado Springs SD #11 Denver Newspaper Agency El Paso County El Paso Department of Health and Environment Intel Corporation Poudre School District Public Employees' Retirement Association (P.E.R.A.) Rocky Mountain Healthcare Coalition State of Colorado Sun Microsystems, Inc. TIAA-CREF University of Colorado Wild Oats Markets, Inc. Woodward Governor

2

Introduction

The Colorado Business Group on Health (CBGH) is pleased to present the **Colorado Type 2 Diabetes Report** for 2007, an overview of demographic, financial, utilization and pharmacotherapy measures for Type 2 diabetes patients in key local markets in the state of Colorado. The overview also provides state and national benchmarks that can help providers and employers identify better opportunities to serve the needs of their patients. All data are drawn from the Therapeutics Trends Summary[™] (TTS), part of the sanofi-aventis **Managed Care Digest Series**[®].


The **Colorado Type 2 Diabetes Report** for 2007 helps CBGH to fulfill its mission to help local employers play an active and enthusiastic role in collaboration with health plans, providers and purchasers; and to be a catalyst in promoting cost-effective delivery of quality health care to the benefit of the community.

This third edition features a number of examples of the kinds of patient-level, disease-specific data on Type 2 diabetes that can be provided by CBGH using the TTS resource. CBGH chose Type 2 diabetes (high blood glucose levels caused by either a lack of insulin or the body's inability to use insulin efficiently) as the focus of this resource, as the Centers for Disease Control estimate that 90% to 95% of all Americans with diabetes—translating to 5.7% of the U.S. population—have the Type 2 variety.

The data in this report (covering 2004 through 2006) were gathered by Verispan LLC, Yardley, Pa., a leading health care consulting and marketing research firm. Verispan maintains the largest patient-centric database in the health care industry.

Publication Notes:

Professional charges are those generated by the providers delivering care to Type 2 diabetes patients in various settings. Hospital Charge figures reflect the charges generated for Type 2 diabetes patients by the facilities that delivered care. Commercial Insurance payers include commercial insurance companies, Blue Cross/Blue Shield, HMOs, PPOs, point-of-service plans and exclusive provider organizations. Verispan did not provide Hospital Charge data for the Colorado Springs and Greeley MSAs.



AVERAGE ANNUAL PROFESSIONAL INPATIENT CHARGES FOR TYPE 2 DIABETES PATIENTS, 2006


Data source: Verispan LLC © 2007

DEMOGRAPHICS: AGE AND GENDER										
	Percentage of Type 2 Diabetes Patients									
AGE GROUP	2004	2005	2006							
0-17	0.4%	0.4%	0.4%							
18–35	4.1	4.9	4.5							
36-64	67.8	67.6	58.4							
65–79	21.7	21.5	29.6							
80+	6.1	5.6	7.2							
GENDER										
Male	38.2%	37.5%	36.8%							
Female	61.8	62.5	63.2							

DEMOGRAPHICS: COMORBIDITIES AND COMPLICATIONS

	Percentage of Type 2 Diabetes Patients							
COMORBIDITIES	2004	2005	2006					
0	30.2%	31.8%	34.9%					
1	24.0	24.4	24.1					
2	31.7	30.7	29.2					
>2	14.1	13.1	11.8					
COMPLICATIONS	11	1011	1110					
0	50.4%	50.5%	50.0%					
1	32.2	33.0	33.6					
2	11.9	12.3	12.1					
>2	5.6	4.3	4.4					

AVERAGE ANNUAL PROFESSIONAL CHARGES FOR TYPE 2 DIABETES PATIENTS




AVERAGE ANNUAL PROFESSIONAL CHARGES FOR TYPE 2 DIABETES PATIENTS, BY PAYER

	Commercial Insurance		Medicaid			Medicare			Government			
	2004	2005	2006	2004	2005	2006	2004	2005	2006	2004	2005	2006
Hospital Inpatient	\$3,204	\$4,249	\$5,136	_	\$4,597	\$4,477	\$3,255	\$4,981	\$4,279	\$1,232	\$2,288	_
Hospital Outpatient	680	1,112	1,352	\$4,802	_	3,289	2,293	4,415	1,872	4,485	1,659	_
Office / Clinic	958	1,650	1,360	1,322	762	540	2,057	1,930	—	3,310	5,897	\$3,224


	UTILIZATION: PERCENTAGE OF TYPE 2 DIABETES PATIENTS, BY SERVICE												
	A1C Test	Serum Cholesterol	Urine Glucose Test	Ophthalmologic Examination									
2004	78.3%	84.0%	88.8%	70.8%									
2005	79.7	85.3	88.3	73.2									
2006	77.7	84.6	90.5	71.5									



PHARMACOTHERAPY: PERCENTAGE OF PATIENTS, BY TYPE OF DRUG THERAPY



PHARMACOTHERAPY: AVERAGE ANNUAL CHARGES BY TYPE OF DRUG THERAPY




DENVER

	DEMOGRAPHICS: AGE AND GENDER											
	Percentage of Type 2 Diabetes Patients											
AGE GROUP	2004	2005	2006									
0-17	0.5%	0.5%	0.6%									
18–35	4.5	5.0	4.1									
36-64	64.6	62.0	55.7									
65–79	23.7	25.0	29.9									
80+	6.7	7.6	9.8									
GENDER												
Male	42.2%	40.3%	41.5%									
Female	57.8	59.7	58.5									

PHARMACOTHERAPY: PERCENTAGE OF


PHARMACOTHERAPY: PERCENTAGE OF PATIENTS, BY TYPE OF DRUG THERAPY



DEMOGRAPHICS: COMORBIDITIES AND COMPLICATIONS

	Percentage of Type 2 Diabetes Patients								
COMORBIDITIES	2004	2005	2006						
0	27.5%	32.2%	36.4%						
1	26.4	23.7	22.7						
2	34.0	32.4	31.1						
>2	12.1	11.7	9.8						
COMPLICATIONS									
0	56.8%	56.6%	57.2%						
1	29.8	29.8	30.3						
2	10.2	10.3	9.6						
>2	3.2	3.4	2.9						

PHARMACOTHERAPY: AVERAGE ANNUAL CHARGES BY TYPE OF DRUG THERAPY



UTILIZATION: PERCENTAGE OF TYPE 2 DIABETES PATIENTS, BY SERVICE


	A1C Test	Serum Cholesterol	Urine Glucose Test	Ophthalmologic Examination
2004	79.2%	85.0%	88.5%	69.4%
2005	79.3	84.9	88.1	68.6
2006	77.9	83.3	88.4	68.4

Data source: Verispan LLC © 2007

4




AVERAGE ANNUAL PROFESSIONAL CHARGES FOR TYPE 2 DIABETES PATIENTS



AVERAGE ANNUAL PROFESSIONAL CHARGES FOR TYPE 2 DIABETES PATIENTS, BY PAYER

	Comm	ercial Insu	irance		Medicaid		Medicare			Government		
	2004	2005	2006	2004	2005	2006	2004	2005	2006	2004	2005	2006
Ambulatory												
Surgery	\$926	\$993	\$1,119	\$1,534	\$2,688	\$2,662	\$2,566	\$2,369	\$2,650	—	—	\$1,103
Hospital												
Inpatient	3,392	3,218	2,884	4,210	3,047	3,045	4,154	3,297	3,722	\$3,467	\$2,857	2,868
Hospital												
Outpatient	1,470	1,430	1,886	—	1,614	1,497	1,587	1,485	1,767	—	1,839	1,300

AVERAGE ANNUAL HOSPITAL CHARGES FOR TYPE 2 DIABETES PATIENTS*




AVERAGE ANNUAL HOSPITAL CHARGES FOR TYPE 2 DIABETES PATIENTS, BY PAYER*

	Commercial Insurance		Medicaid			Medicare			Government			
	2004	2005	2006	2004	2005	2006	2004	2005	2006	2004	2005	2006
Emergency Room	\$1,433	\$1,153	\$1,120	\$1,832	\$1,368	\$1,329	\$2,230	\$1,812	\$1,655	\$1,464	\$2,641	\$1,336
Hospital Outpatient	2,191	1,717	2,119	2,673	2,339	2,684	3,472	2,564	3,174	1,449	2,644	2,152
Hospital Inpatient	23,179	18,211	32,025	58,737	68,297		30,067	23,416	34,651	19,285	—	_

6

	DEMOGR AGE AND			DEN COMORBIDITI	IOGRAPI ES AND C		TIONS		
	Percentage	of Type 2 Diabe	tes Patients		Percentage of Type 2 Diabetes Patients				
AGE GROUP	2004	2005	2006	COMORBIDITIES	2004	2005	2006		
0–17	0.9%	0.3%	0.3%	0	32.4%	36.6%	44.7%		
18–35	4.2	4.4	5.2	1	23.1	21.2	20.0		
36-64	61.9	62.5	54.9	2	31.6	30.3	27.5		
64–79	25.2	24.8	29.3	>2	13.0	11.9	7.9		
80+	7.7	8.1	10.2	COMPLICATIONS					
GENDER				0	53.3%	57.5%	62.5%		
Male	41.9%	41.4%	41.7%	1	32.0	29.3	27.1		
Female	41.9% 58.1	41.4% 58.6	58.3	2 >2	11.8 2.9	11.2 2.0	8.5 1.9		

AVERAGE ANNUAL PROFESSIONAL CHARGES FOR TYPE 2 DIABETES PATIENTS



AVERAGE ANNUAL PROFESSIONAL CHARGES FOR TYPE 2 DIABETES PATIENTS, BY PAYER*


	Commercial Insurance		Medicaid			Medicare			Government			
	2004	2005	2006	2004	2005	2006	2004	2005	2006	2004	2005	2006
Hospital Inpatient	\$1,995	\$2,306	\$1,473	\$4,140	\$2,154	_	\$2,648	\$2,382		_	\$1,463	_
Hospital Outpatient	764	735	979	1,241	1,083	\$1,496	1,011	1,191	\$1,150	3,218	2,450	\$2,746
Office / Clinic	1,276	796	566	594	766	606	1,928	1,587	_	1,174	434	_

AVERAGE ANNUAL HOSPITAL CHARGES FOR TYPE 2 DIABETES PATIENTS, BY PAYER TYPE, 2006


	Managed Care/ Commercial Insurance	Medicaid	Medicare	Government	OVERALL AVERAGE
Emergency					
Room	\$982	\$2,150	\$2,183	\$1,195	\$1,811
Hospital					
Outpatient	1,884	3,925	3,923	3,653	3,164
Hospital					
Inpatient	28,442	34,754	46,310	39,030	41,126



PHARMACOTHERAPY: PERCENTAGE OF PATIENTS, BY TYPE OF DRUG THERAPY



PHARMACOTHERAPY: AVERAGE ANNUAL CHARGES BY TYPE OF DRUG THERAPY



UTILIZATION: PERCENTAGE OF TYPE 2 DIABETES PATIENTS, BY SERVICE							
	A1C Test	Serum Cholesterol	Urine Glucose Test	Ophthalmologic Examination			
2004	76.4%	82.7%	86.7%	73.2%			
2005	77.9	83.3	85.2	77.9			
2006	78.0	81.9	87.5	80.8			

GRAND JUNCTION

DEMOGRAPHICS: AGE AND GENDER						
	Percentage	e of Type 2 Diabe	tes Patients			
AGE GROUP	2004	2005	2006			
18–35	1.6%	1.1%	0.3%			
36–64	42.1	38.3	36.7			
64–79	46.2	46.4	47.6			
80+	10.0	14.2	15.4			
GENDER						
Male	50.0%	51.3%	50.9%			
Female	50.0	48.7	49.1			


DEMOGRAPHICS: COMORBIDITIES AND COMPLICATIONS

	Percentage of Type 2 Diabetes Patients					
COMORBIDITIES	2004	2005	2006			
0	23.7%	25.9%	41.5%			
1	26.1	25.8	20.7			
2	31.6	32.7	26.5			
>2	18.7	15.6	11.4			
COMPLICATIONS						
0	34.5%	34.0%	36.4%			
1	47.0	51.5	48.0			
2	13.9	10.9	11.8			
>2	4.7	3.6	3.7			

UTILIZATION: PERCENTAGE OF TYPE 2 DIABETES PATIENTS, BY SERVICE

	A1C Test	Serum Cholesterol	Urine Glucose Test	Ophthalmologic Examination
2004	75.7%	84.6%	89.7%	64.0%
2005	79.8	79.8	93.0	72.1
2006	78.0	88.0	86.0	63.0


AVERAGE ANNUAL PROFESSIONAL CHARGES FOR TYPE 2 DIABETES PATIENTS




AVERAGE ANNUAL PROFESSIONAL CHARGES FOR TYPE 2 DIABETES PATIENTS, BY PAYER*

Comm	ercial Insu	irance		Medicaid			Medicare		C	Governmen	t
2004	2005	2006	2004	2005	2006	2004	2005	2006	2004	2005	2006
\$3,101	\$3,258	\$2,422	\$2,853	\$1,404	\$4,354	\$3,612	\$3,121	\$3,015	—	—	
804	882	761	2,170	—	1,300	908	1,138	858	—	—	—
682	941	880	1,300		1,453	772	988	933	520	773	206
	2004 \$3,101 804	2004 2005 \$3,101 \$3,258 804 882	\$3,101 \$3,258 \$2,422 804 882 761	2004 2005 2006 2004 \$3,101 \$3,258 \$2,422 \$2,853 804 882 761 2,170	2004 2005 2006 2004 2005 \$3,101 \$3,258 \$2,422 \$2,853 \$1,404 804 882 761 2,170 —	2004 2005 2006 2004 2005 2006 \$3,101 \$3,258 \$2,422 \$2,853 \$1,404 \$4,354 804 882 761 2,170 — 1,300	2004 2005 2006 2004 2005 2006 2004 \$3,101 \$3,258 \$2,422 \$2,853 \$1,404 \$4,354 \$3,612 804 882 761 2,170 — 1,300 908	2004 2005 2006 2004 2005 2006 2004 2005 \$3,101 \$3,258 \$2,422 \$2,853 \$1,404 \$4,354 \$3,612 \$3,121 804 882 761 2,170 — 1,300 908 1,138	2004 2005 2006 2004 2005 2006 2004 2005 2006 2004 2005 2006 \$3,101 \$3,258 \$2,422 \$2,853 \$1,404 \$4,354 \$3,612 \$3,121 \$3,015 804 882 761 2,170 — 1,300 908 1,138 858	2004 2005 2006 2004 2005 2006 2004 2005 2006 2004 2005 2006 2004 2004 2004 \$3,101 \$3,258 \$2,422 \$2,853 \$1,404 \$4,354 \$3,612 \$3,121 \$3,015 804 882 761 2,170 1,300 908 1,138 858	2004 2005 2006 2004 2005 2006 2004 2005 2006 2004 2005 2006 2004 2005 \$3,101 \$3,258 \$2,422 \$2,853 \$1,404 \$4,354 \$3,612 \$3,121 \$3,015 804 882 761 2,170 1,300 908 1,138 858

PHARMACOTHERAPY: PERCENTAGE OF PATIENTS, BY TYPE OF DRUG THERAPY



PHARMACOTHERAPY: AVERAGE ANNUAL CHARGES BY TYPE OF DRUG THERAPY



Data source: Verispan LLC © 2007


8

DEMOGRAPHICS: AGE AND GENDER							
	Percentage	Percentage of Type 2 Diabetes Patients					
AGE GROUP	2004	2005	2006				
0–17	0.2%	0.3%	0.3%				
18–35	6.8	6.1	6.9				
36-64	62.5	66.9	57.7				
64–79	24.5	20.6	26.2				
80+	6.0	6.1	9.0				
GENDER							
Male	27.6%	28.1%	30.6%				
Female	72.4	71.9	69.4				

DEMOGRAPHICS: COMORBIDITIES AND COMPLICATIONS

COMORBIDITIES AND COMPLICATIONS						
	Percentage of Type 2 Diabetes Patients					
COMORBIDITIES	2004	2005	2006			
0	31.2%	35.9%	44.5%			
1	24.7	23.0	22.0			
2	31.8	28.1	24.3			
>2	12.3	13.0	9.2			
COMPLICATIONS						
0	54.5%	54.6%	54.4%			
1	31.3	32.2	35.5			
2	11.2	10.4	8.3			
>2	3.0	2.9	1.8			

AVERAGE ANNUAL PROFESSIONAL CHARGES FOR TYPE 2 DIABETES PATIENTS




AVERAGE ANNUAL PROFESSIONAL CHARGES FOR TYPE 2 DIABETES PATIENTS, BY PAYER*

	Comm	nercial Insu	arance		Medicaid			Medicare		(Governmen	nt
	2004	2005	2006	2004	2005	2006	2004	2005	2006	2004	2005	2006
Hospital Inpatient	\$2,357	\$1,618	\$1,622	\$1,531	_	\$2,433	\$1,184	\$2,244	\$1,120	_	\$694	_
Hospital Outpatient	656	546	916	509	_	436		599		_	_	\$840
Office / Clinic	485	435	453	377	\$272	400	607	853			285	277


	UTILIZATION: PERCENTAGE OF TYPE 2 DIABETES PATIENTS, BY SERVICE						
	A1C Test	Serum Cholesterol	Urine Glucose Test	Ophthalmologic Examination			
2004	79.5%	80.5%	88.8%	70.7%			
2005	74.3	80.3	84.9	64.2			
2006	80.1	81.6	87.5	65.8			



PHARMACOTHERAPY: PERCENTAGE OF PATIENTS, BY TYPE OF DRUG THERAPY




PHARMACOTHERAPY: AVERAGE ANNUAL CHARGES BY TYPE OF DRUG THERAPY



PUEBLO

DEMOGRAPHICS: AGE AND GENDER						
	Percentage	of Type 2 Diabe	tes Patients			
AGE GROUP	2004	2005	2006			
0–17	0.3%	0.5%	0.5%			
18–35	3.5	3.8	4.6			
36–64	54.0	53.9	52.2			
64–79	32.5	32.3	32.0			
80+	9.7	9.6	10.7			
GENDER						
Male	38.1%	36.7%	36.5%			
Female	61.9	63.3	63.5			


PHARMACOTHERAPY: PERCENTAGE OF PATIENTS, BY TYPE OF DRUG THERAPY



DEMOGRAPHICS: COMORBIDITIES AND COMPLICATIONS

	Percentage of Type 2 Diabetes Patients					
COMORBIDITIES	2004	2005	2006			
0	37.4%	45.8%	55.6%			
1	26.7	23.3	18.2			
2	26.3	22.8	19.8			
>2	9.5	8.1	6.5			
COMPLICATIONS						
0	53.8%	55.9%	63.4%			
1	31.3	31.0	26.3			
2	11.3	9.9	7.9			
>2	3.7	3.1	2.4			

PHARMACOTHERAPY: AVERAGE ANNUAL CHARGES BY TYPE OF DRUG THERAPY



UTILIZATION: PERCENTAGE OF TYPE 2 DIABETES PATIENTS, BY SERVICE


	A1C Test	Serum Cholesterol	Urine Glucose Test	Ophthalmologic Examination		
2004	75.7%	80.7%	87.3%	66.7%		
2005	79.2	82.0	84.1	68.4		
2006	76.6	83.1	89.7	69.9		

Data source: Verispan LLC © 2007

10



AVERAGE ANNUAL PROFESSIONAL CHARGES FOR TYPE 2 DIABETES PATIENTS




AVERAGE ANNUAL PROFESSIONAL CHARGES FOR TYPE 2 DIABETES PATIENTS, BY PAYER*

	Commercial Insurance		Medicaid			Medicare			Government			
	2004	2005	2006	2004	2005	2006	2004	2005	2006	2004	2005	2006
Hospital Inpatient	\$1,426	\$1,703	\$1,182	\$652	\$1,859	\$925	\$1,451	\$1,050	\$994	\$1,403		\$2,040
Hospital Outpatient	264	306	320	280	418	332	319	281	318	55	_	_
Office / Clinic	466	637	587	536	854	_	715	907	544	593	592	724

AVERAGE ANNUAL HOSPITAL CHARGES FOR TYPE 2 DIABETES PATIENTS, BY PAYER TYPE, 2006

	Managed Care/ Commercial Insurance		Medicaid			Medicare			Government			
	2004	2005	2006	2004	2005	2006	2004	2005	2006	2004	2005	2006
Emergency												
Room	\$1,344	\$1,402	\$1,384	\$1,883	\$2,021	\$1,968	\$1,627	\$1,584		\$1,448	\$1,240	\$1,158
Hospital												
Outpatient	2,753	2,855	2,892	3,650	4,092	3,905	3,521	1,418	—	2,702	2,679	2,550
Hospital												
Inpatient	32,702	38,320	34,819	41,393	45,589	48,515	33,106	8,236	—	26,006	47,226	30,991

AVERAGE ANNUAL HOSPITAL CHARGES FOR TYPE 2 DIABETES PATIENTS



Data Methodology

Through agreements with more than three dozen data providers, Verispan receives data from more than 425 million health care professional and institutional claims annually, representing over 200 million unique patients, or approximately 30% of all such claims in the U.S. Data from physicians of all specialties and from all hospital types are presented in the TTS.

Verispan also gathers data on prescription activity from the National Council for Prescription Drug Programs (NCPDP). These data represent some 5 billion prescription claims annually, or approximately 54% of the prescription universe. These data represent the sampling of prescription activity from a variety of sources, including retail chains, mass merchandisers and pharmacy benefit managers, and come from a near census of more than 59,000 pharmacies in the U.S. Cash, mail-order, Medicaid, and third-party transactions are tracked.


DATA INTEGRITY

Data arriving into Verispan are put through a rigorous process to ensure that data elements match to valid references, such as product codes, ICD-9 (diagnosis) and CPT-4 (procedure) codes, and provider and facility data.

Claims undergo a careful de-duplication process to ensure that when multiple, voided, or adjusted claims are assigned to a patient encounter, they are applied to the database, but only for a single, unique patient.

Through its patient encryption methods, Verispan creates a unique, random numerical identifier for each patient, then strips away all patient-specific health information that is protected under the Health Insurance Portability and Accountability Act (HIPAA). The identifier allows Verispan to track disease-specific diagnosis and procedure activity across the various settings where patient care is provided (hospital inpatient, hospital outpatient, emergency rooms, clinics, doctors' offices and pharmacies), whileprotecting the privacy of each patient.

COLORADO TYPE 2 DIABETES PATIENT CLAIMS,



* Other includes self-pay and workers' compensation.



CBGH